NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
News from Endpoints News: NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
NodThera
Clinical-stage biotechnology developing brain-penetrant NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory diseases